A detailed history of Gamma Investing LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Gamma Investing LLC holds 118 shares of CRNX stock, worth $6,362. This represents 0.0% of its overall portfolio holdings.

Number of Shares
118
Previous 65 81.54%
Holding current value
$6,362
Previous $2.91 Million 107.15%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 04, 2024

BUY
$43.83 - $54.98 $2,322 - $2,913
53 Added 81.54%
118 $6.03 Million
Q2 2024

Jul 02, 2024

BUY
$42.12 - $51.91 $294 - $363
7 Added 12.07%
65 $2.91 Million
Q1 2024

Apr 05, 2024

BUY
$34.76 - $46.81 $556 - $748
16 Added 38.1%
58 $2.72 Million
Q4 2023

Feb 01, 2024

BUY
$25.62 - $37.07 $1,076 - $1,556
42 New
42 $1.53 Million

Others Institutions Holding CRNX

About Crinetics Pharmaceuticals, Inc.


  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $2.9B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Gamma Investing LLC Portfolio

Follow Gamma Investing LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gamma Investing LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gamma Investing LLC with notifications on news.